		n 1449A/PTO (Modified) heets as necessary)	Attorney Docket No.: Application Number: 04646.P007X 09/809,870			er:	
			First Named Invent Jesse Salb, et al.	or			
Page 1	of <u>1</u>	_	Filing Date: 3/15/2001				
		OTHER ART - NO PATEN	NT LITERATURE DO	CUMEN	TS	-	•
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL of the item (book, magazine, journal, se issue number(s), publishe	rial, symposium, catalog	g, etc.), date	e, page(s), v	ite), title olume-	Translation <sup>2</sup>
MP SIGEL, PETER and PETTE, DIRK. " glycolytic enzymes in white and rec coupled enzyme reactions in histoch Cytochemistry, vol. 17, no. 4; pages			abbit skeletal muscle; mistry." The Journal	a gel film of Histoch	method fo	r j	
						-	
			·	•	,	•	ì
			·				
Comme to a				Date Cor	cidered		
Examiner Signature		/Melissa Perreira/		Date Cor	Pincien	06/2	23/2006

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<sup>&#</sup>x27;Unique citation designation number. 'Applicant is to place a check mark here if English language Translation is attached.

		n 1449A/PTO (Modified) sheets as necessary)	Attorney Docket N 04646.P007X	o.:	Applicate 09/809,	ion Numb ,870	er:
			First Named Inven Jesse Salb, et al.	tor:			
Page 1	of <u>1</u>	·	Filing Date: 3/15/2001				
		OTHER ART - NO PATEN	T LITERATURE DO	OCUMEN	TS ·	• • • • • • • • • • • • • • • • • • •	
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAI of the item (book, magazine, journal, se issue number(s), publishe	rial, symposium, catalo	x, etc.), date	e, page(s), v	ate), title volume-	Translation <sup>2</sup>
MP		BECH, LARS; DIEMER, NILS HENRI topical application of metrizamide to pages 427-431 (June 1985).	K; and GJEDDE, ALE rat brain cortex." Ac	BERT. "Me ta Neurol S	tabolic eff	ect of . 72,	•
MP		GJEDDE, ALBERT. "The blood-brain Neurol. Scandinay. vol. 66, pages 392-		ole to metri	zamide."	<u>Acta</u>	
		glycolytic enzymes in white and red r coupled enzyme reactions in histoche Cuto 1 200 No. 17, no. 4 (September 1987)	abbit skeletal muscre mistry." The Journal	a gel film	method fo	)r	
							0
		·				•	
						_	
				•			
· ·				Data C	at dame d		
Examiner Signature		/Melissa Perreira/		Date Con	siaerea	06,	/23/2006

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<sup>&#</sup>x27;Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substit	ute for I	Form 1449A/PT any sheets as neces	O (Modified) sary)	Attorney Docket N 04646.P007X	O: Application N 09/809,870	umber:
				First Named Inven Jesse Salb	tor:	
Page _	1 of _			Filing Date: 3/15/2001		
				U.S. PATENT DOCUMENTS		
Exam.	Cite	U.S. Patent		Name of Patentee or Applicar	nt Date of	Pages, Columns,
Initial*	No.1	Number	Kind Code (If known)	of Cited Document	Publication of Cited Document MM-DD-YYYY	Lines, Where Relevant Passages or Relevant Figures Appear
MP			6,226,352	. B1	Salb	05-01-2001
MP			US2001/ 0038682	A1	Salb	11-08-2001
	-					
		,				
						,
			·			
			<u> </u>			
	<u></u>					

Exam.	Cite				Foreign Patent Document Name of Patentee or Applicant				T
Initial*	No.1	Office	Number <sup>4</sup>	Kind Co (If kno		of Cited Document	Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
MP		WIPO	WO 01,	67958	A2	Veritas Pharmaceuticals, Inc.	9-20-2001		

Examiner	Maliasa Dammaina/	Date Considered	06/23/2006
Signature	/Melissa Perreira/		00/23/2000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>2</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard S.3). <sup>4</sup>For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>4</sup>Applicant is to place a check mark here if English language Translation is attached.

		n 1449A/PTO (Modified) heets as necessary)	Attorney Docket No.: 04646.P007X	Application Numb 09/809,870	er:
	_	·	First Named Inventor: Jesse Salb		
Page 2	of <u>2</u>	=	Filing Date: 3/15/2001		
•		OTHER ART - NO PATEN	IT LITERATURE DOCUMEN	TS	
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL of the item (book, magazine, journal, se issue number(s), publishe		e, page(s), volume-	Translation <sup>2</sup>
MP		PCT International Search Report for Po August 2002 (9 pages).	CT Int'l Appin No. US01/08612	2, mailed 16	
MP XU, YIMING et al. "Synthesis of Radioiodinated 1-Deoxy-Nojirimycin Derivatives: Novel Glucose Analogs," <u>Nuclear Medicine and Biology</u> , Vol. 26, No. 7, p. 833-839 (1999), Document No. XP-001037809.				in Derivatives: . 7, p. 833-839	
MP	·	MAGATA, YASUHIRO et al. "Develo Derivative with Interaction to Hexokin Radiopharmaceuticals, Vol. 31, No. 4,	nase," Journal of Labelled Com	pounds and	
MP		LUTZ, T. et al. "123I-Iodobenzoylgluco Imaging," <u>Iournal of Labelled Compo</u> p. 327-344 (1993), Document No. XP-0	unds and Radiopharmaceutical	or Heart <u>ls</u> , Vol. 33, No. 4,	
			:		
					·

Examiner		Date Considered	06/23/2006
Signature	/Melissa Perreira/		00/23/2000

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

## Notice of References Cited Application/Control No. 09/809,870 Examiner Lauren Q Wells Applicant(s)/Patent Under Reexamination SALB ET AL. Page 1 of 2

## U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
М	Α .	US-4243653	01-1981	Sovak et al.	424/5
М	В	US-3701771	10-1972	Almen et al.	260/211
MP	С	US-4455292	06-1984	Bertoni	424/5
MP	D	US-3974386	10-1976	Mistretta et al.	250/402
М	, E	US-3854049	12-1974	Mistretta et al.	250/402
MP	F	US-4139605	02-1979	Felder et al.	424/5
MP	G	US-4250113	02-1981	Nordal et al.	564/163
ME	н	US-4160015	07-1979	Wiegert	424/5
MP	ī	US-3702866	11-1972	Salvesen et al.	260/501.11
MP	J	US-4341756	07-1982	Sovak et al.	424/5
MP	к	US-4352788	10-1982	Felder et al.	424/5
MP	L	US-4348377	10-1982	Felder et al.	· 424/5
MP	М	US-4439613	03-1984	Sovak et al.	549/347

## FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	. Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S	•				
	Т					

## NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	٧	
	8	·
	×	

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

# Application/Control No. Applicant(s)/Patent Under Reexamination SALB ET AL. Examiner Art Unit Page 2 of 2

## U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
М	A	US-4766110	08-1988	Ryan et al.	514/19
MI	В	US-4021481	05-1977	Almen et al.	260/558
MF	С	US-2840602	06-1958	Larsen	260/518
MP	D	US-5609851	03-1997	Bennani et al.	424/9.454
MP	Ε	US-5525327	06-1996	Baker et al.	424/9.45
MP	F	US-4406878	09-1983	DeBoer .	424/5
	G	US-		·	
	H	US-			
	ı	US			
	7	US-			
	К	US-			
	L	US+			
	М	US-			

## **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	s					
	Т					

## NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	υ	
	٧	·
	8	
	X	

"A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known					
Application Number 09/809,870					
	March 15, 2001				
First Named Inventor	Jesse Salb				
Art Unit	2877				
Examiner Name					
Attorney Docket Number	04646.P007X				

			U.S. PATE	NT DOCUMENTS	
Exeminer Initials	Cite No.1	_Document Number Number-Kind Code <sup>2</sup> (If known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MP	L	US- 4,474,747	10 - 02 - 1984	Dimo et al.	
MP		US- 4,887,604	12 - 19 - 1989	Shefer et al.	
MP		US- 5,043,152	08 - 27 - 1991	Schaefer et al.	
MP	1	US- 5,609,851	03 - 11 - 1997	Bennani et al.	
MP	l'''''	us. 5,817,289	10 - 06 -1998	Klaveness et al.	
MP		US- 6,071,491	06 - 06 - 2000	Epstein et al.	
MP		us- 5,650,135	07-22-1997	Contag et al.	
MP	<u> </u>	us- 5,796,862	08-18-1998	Pawlicki et al.	
	<u> </u>	U3-			
	<b></b>	US-		***************************************	
	<u> </u>	US-			
	<b>.</b>	US-			
	<u> </u>	US-			
		US-			
		US-			
		US-	1		
		US-			
		US-			
***************************************		US-			
••••••••	Ī	US-			

	FOREIGN PATENT DOCUMENTS											
Examiner Initials		Foreign Patent Document  Coursy Code 3 - Number 4 - Idnd Code 4 / Income	Publication Date MM-DD-YYYY	Name of Patentes or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6						
			····			. <b>.</b> .						
	•		***************************************		***************************************							
			•									

Examiner	/Melissa Perreira/	Date	06/23/2006
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspio.nev">www.uspio.nev</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTC/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	or form 14498/PTQ	>	-	Complete if Known		
INFOR	MATION	DIC	OL OCUPE	Application Number	09/809.870	
INFUR	MOHAM	זוטוז	SCLOSURE	Filing Date	March 15, 2001	
STATI	EMENT B	Y A	PPLICANT	First Named Inventor	Jesse Salb	
• • • • • • • • • • • • • • • • • • • •		<b>-</b>		Group Art Unit	2877	
	(use as many sh	heets a	s necessary)	Examiner Name		
Sheet 2 of 4				Attorney Docket Number	04646.P007X	

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country whem published.	
MP		ANDERSON et al., "What does positron emission tomography offer oncology?". Eur. J. Cancer 38:2028-2035 (2000).	
MP		BENDER et al., "Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer", Hybridoma 18: 87-91 (1999).	
BROCK et al., "Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade glomas". Br. J. Cancer 82:608-615 (2000).			
MP CONTI et al., "PET and [18F]-FDG in oncology: a clinical update", Nuc. Med. Biol. 23:717-735 (1996).			
MP		DEHDASHTI et al., "Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy", Eur. J. Nucl. Med. 26: 51-56 (1999).	
МР		FINDLAY et al., "Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases; correlation with tumor response to fluorouracit", J. Clin. Oncol. 14: 700-708 (1996).	
MP		FISCHMAN, "Positron Emission Tomography in the Clinical Evaluation of Metastatic Cancer", J. Clin. Oncol. 14: 691-698 (1998).	
MP		FISCHMAN, "The role of positron emission tomography in pharmacokinetic analysis", <i>Drug Metab.</i> Rev. 29: 923-956 (1997).	•••
MP		FOWLER et al., "PET and drug research and development". J. Nucl. Med. 40:1154-1163 (1999).	
MP		GERAN et al., "Protocols for screening chemical agents and natural products against animal tumors and other biological systems", Cancer Chemother. Rep. 3: 51-61 (1972).	
MP		GREEN et al., "Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose", J. Nucl. Med. 39: 729-734 (1998).	

-				
ſ	Examiner	/Melissa Perreira/	Date	06/23/2006
l	Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTC/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute !	for form 1448B/PTC	<b>)</b>	-	Complete if Known		
INFO	MATION	DIO	OL OCUPE	Application Number	.09/809.870	
INFOR	<b>KMAHUN</b>	012	CLOSURE	Filing Date	March 15, 2001	
STAT	EMENT B	Υ ΔΙ	PPLICANT	First Named Inventor	Jesse Salb	
				Group Art Unit	2877	
	(use as many st	reets as	necessary)	Examiner Name		
Sheet	3	of	4	Attorney Docket Number	04646.P007X	

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	1
MP		HENDRIKSE et al., "Visualization of multidrug resistance in vivo". Eur. J. Nucl. Med. 26:283-293 (1999).	
MP	********	HIETALA, "Ligand-receptor interactions as studied by PET: implications for drug development", Ann. Med. 31: 438-443 (1999).	
MP		HOH et al., "PET in oncology: will it replace the other modalities?", Semin. Nuc. Med. 27:94-108 (1997).	
МР		HOEY & SMITH, in Sovak ed., "Handbook of Experimental Pharmacology: Radiocontrast Agents", 73: 22-125, Springer-Verlag, NEW YORK (1984).	_
MP		JERUSALEM et al., "Whole-body positron emission tomography using 18F-fluorodeoxyglucose for positreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging", <i>Blood</i> 94: 429-433 (1999).	
MP		KNUUTI et al. "PET as a cardiovascular and metabolic research tool", Ann. Med. 31: 450-456 (1999).	
MP		PRICE & JONES "Can Positron Emission Tomography (PET) be Used to Detect Subdinical Response to Cancer Therapy?", Eur J Cancer 31A: 1924-1927 (1995).	
MP		ROMER et al., "Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose", <i>Blood</i> 91: 4464-4471 (1998).	
MP		SCHELLING et al., "Positron emission tomography using ((18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer". J. Ciln. Oncol. 18:1689-1695 (2000).	
MP		SCHULTE et al., "Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET". J Nucl. Med. 40: 1637-1643 (1999)	~
MP		SMITH et al., "Positron emission tomography using [(18)F]-fluorodecxy-O-glucose to predict the pathologic response of breast cancer to primary chemotherapy". J. Clin. Oncol. 18:1676-1688 (2000).	

Examiner	/Melissa Perreira/	Date	.06/23/2006
Signature		Considered	.06/23/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute (	or form 14498/PT	0	•	Cor	mplete if Known
		-	01 001105	Application Number	09/809,870
INFOR	(MA I ION	I DIS	CLOSURE	Filing Date	March 15, 2001
STAT	EMENT S	RY AI	PPLICANT	First Named Inventor	Jesse Salb
JIAI		<b>3</b> 1 A	LIOAIII	Group Art Unit	2877
	(use as many s	sheets as	necessary)	Examiner Name	
Sheet 4 of 4		Attorney Docket Number	04646.P007X		

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), titls of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	,
MP		SOVAK et al. "Contrast media: a journey almost sentimental". Invest Radiol. 29: Suppl 1:S4-14 (1994).	Ī
MP		VALLBURG et al. "Drug development, radiolabelled drugs and PET", Ann. Med. 31: 432-437 (1999).	Ī
MP		WAHL et al., "Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation", <i>J. Clin. Oncol.</i> 11: 2101-2111 (1993).	
MP		WEBER et al., "Reproducibility of metabolic measurements in malignant tumors using FDG PET", J. Nucl. Med. 11:1771-1777 (1999).	
MP		YOSHIOKA et al., "Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice", J Nucl. Med 38: 714-717 (1997).	
MP		ZHANG et al., "Bioluminescence for biological sensing in living mammals". Adv. Exp. Med. Biol. 471:775-784 (1999).	
MP		PCT International Search Report for PCT Appln No. PCT/US01/08485, mailed 10-24-01 (9 pages).	
MP		PCT International Search Report for PCT Appln No. PCT/US01/08663, mailed 10-24-01 (9 pages).	
			-
************		-	ľ

			O-100
Examiner	/Melissa Perreira/	Date Considered	06/23/2006
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

	·		Notice of Refer	omena Citad		Application/Control 09/149,734	1	Applicant(s)/Pat Reexamination SALB, JESSE	ent Unde	r
			Monca of Malak	ences Cited		Examiner		Art Unit	0	-11
ļ						Armando Rodriguez		2877	Page 1	Of 1
	*		DOCUMENT NO.	DATE	U.S. PA	TENT DOCUMENTS NAME	CLASS	SUBCLASS	DOCUME	-
MP	0	A	4887604	Dec. 1989	Shefer et a	<u> </u>	128	654	APS	OTHER
MP		8	6071491	Jun. 2000	Epstein et a	ai	- 424	1.49	ā	Ø
Ì		C						1		0
		٥							0	
	0	ε								à
	0	F							0	0
		G		·					0	
		н								0
		1								
	0	٦							0	
	0	К								0
	0	Ł								0
	0	М				-				
					FOREIGN	PATENT DOCUMENTS			DOCUME	NT
	*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	APS	OTHER
	0	N								
	0	0								
	0	ρ							0	0
	0	a							0	0
		R							а	
		s							а	
		Т							0	o ·
		<u></u> -			NON-P	ATENT DOCUMENTS			LOOCUME	NT
	•		04	OCUMENT (Including	ng Author, Title	Date, Source, and Perti	inent Pages)		SOURCE	OTHER
	0	U							0	
	0	v							a	
	0	w							0	0
	0	x							0	0

"A copy of this reference is not being furnished with this Office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)
"APS encompasses any electronic search i.e. text, image, and Commercial Databases.
U.S. Patent and Trademark Office
PTO-892 (Rev. 03-98)

Notice of References Cited

Part of Paper No 10

					\ F		?					Sheet1	af _	10	
	Form PT			<b>J</b>				PARTA	HT OF COMMERCE	ATTY, DOCKET NO.		SERIAL NO.			
	(REV. 8-8	13) /		1	. 0	1	ď	1		76958.P00	3	09/	149,73	4	
		1		•				- SI -	_	APPLICANT					
	INFO	RMAT	Ø,	ÍC		CL	0	SUBJE CI	TATION	Jesse Salb					
		(1100	//	<b>~</b>	T <sub>R</sub>	ADE	إد	<b>&gt;</b> /		FRLING DATE		GROUP			
ŀ		(USB.	Sevi	era:	30	0013	7	f necessar	<u> </u>	9-8-98		not ye	t assig	ned	
ļ							_	U.S. PA	TENT DOCL	JMENTS					
	EXAMINER INITIAL		00CU	MEM	T HAUS	482A		OATE		ВМИ	CLASS	SUBCLASS	FR.INC	DATE OPRIATE	
MF	AL		3 7	0	1 7	7	1	10/31/72	Almen et al	•	260	211R	6/26	6/70	
MΡ	M		3 8	5	4 0	4	9	12/10/74	Mistretta et	al.	250	402	12/1	0/73	
ſΡ	Æ		3 9	7	4 3	8	6	8/10/76	Mistretta et	al.	250	402	3/27	7/75	
ſΡ	AL		4 2	424	5	4/27	7/79								
MP	#		4 2	5	564	153	8/24	1/79							
MΡ	All		4 3	6	4 9	2	1	12/21/82	Speck et al		424	5	3/6	/80	
	FOREIGN PATENT DOCUMENTS														
ł	<del></del> 1						٦				<del></del>	SUBCLUSS	TRANSI	ATION	
ļ		00	2014	9AT 1	NUME:		_	DATE	C	OUNTRY	aves	4000	YES	140	
ļ				Ц		Ц				• •		ブンソ			
			Ц	Ц		Ц				ر التراث	$l \otimes \alpha$	no.			
			$\prod_{i}$	Ш								İ			
		•		тн	ER	DC	C	UMENTS	(Includina Aut	hor, Title, Oate, Perti	nent Pag	es. Etc.)			
ł			A	gra	wai		t			oligonucleotides", Cib	•	•	sium 20	79. pp.	
MH	40		Т					tal "The m	echanism of c	egulation of hexokina	sa. saw i	insights from	n the co	vetal	
Ì	- <del>/ - L/ -  </del>		s	truc	ture	of 1	0	combinant h	uman brain he	exokinase complexed			ii die ci	y Star	
м	M	 	18	ucc	750	o-pr	10	эрпиле", З	tructure 6(1):3	a-30 (1,88 <b>0)</b> *					
	144		+	ller	C.E	3. et	8	., "Flow cyte	ometric analys	is of glucose transpo	rt by rat b	rain cells".	Cytom	etry	
MP	10	-	5	7:20	62-2	268	1	997).		•					
М	X#	-	A	lpe	n N	.M. (	t	al., "Improve	ed methods fo	r image registration*,	Neuroim	age 3:10-18	3 (1996 <u>)</u>		
ا _	10	<u> </u>								e of mitochondrial bo					
ΩP	AL									nosphorylation of glu :17422-17428 (Nov.			нопалу		
м	11	<u> </u>		am	ett	j.F	3	et al. *Ste	ctural remire	nents for binding to (	he sugar	-transport e	vstem n	f the	
	14	-								1-221 (1973).					
М	. <i></i> /	L	-	300	oH.	160	3	et al *Evir	leace for two	asymmetric conforma	itional eta	tes in the h	uman		
	4									ochem. J. 145:417-4			a1		
	EXAMINI	ER	1	, ,		•	ı		O/	TE CONSIDERED	/				
	11/	tren	$\gamma^{\iota}$	0	Y	.90	ļ;	3452		7/22/	PD				
										ion is in conformance					
	through ci applicant.		not i	n co	onto	ıma	Λŧ	se and not c	onsidered. In	clude copy of this for	m with ne	NT COMMUN	ication (		

06/23/2006

			/	5	VI	P	E	<u>`</u>	\					-		5	Sheet 2	at	10
	Form PT (REV. 8-		9		R O						ENT OF COMMERCI PADEMARK OFFICE	<b>E</b> ^	7 Tr		NO. 8.PO		SERIAL NO.	149,73	14
	****				-			•	્ડ્	<u>/</u>		- 1	PPUCAY			<del></del> -			
	. INFO	HMAY	(A)	アン	DI Zaz	15 40	Cr Cr	S	yu	JRE CI	ITATION	⊢	Jesse		<u> </u>		GROUP		
		(Use	Se					is i	if ne	cessary	y)			9-8	3-98		not ye	et assig	ned
	<del></del>	<del></del>			_	_			<u>,                                    </u>	U.S. PA	TENT DOC	UM	ENTS	3					
	'EXAMINER INITIAL		000		ENT	NUS	48E)	,   —	Ļ	OATE		NA.	WE			CASS	SUBCLASS	FILIN IF APPE	G DATE OPRIATE
P	AL		4	4	5 5	<u>;</u>  2	2 9	2	6/	/19/84	Bertoni					424	5	4/5	5/82
P	12		4	7	1 6	3 2	2 2	5	12	2/29/87	Ledley et a	ai.				536	122	9/3	0/85
₽	AL	- -	5	1	4 1	1/7	7 3	9	8/	/25/92	Jung et al.					424	4	4/2	2/91
	Al_	-	5	4	0 8	1 9	19	6	4/	/25/95	Salb					128	633	3/2	5/93
7	AL	igsqcup	5	4	6 6	华	<u> </u>  8	6	11	/14/95	Buhr et al.					536	26.26	.5/1	0/94
₽	AL		5	6	1 0	) 2	8	9	3/	/11/97	Cook et al.					536	25.34	4/7	7/94
	FOREIGN PATENT DOCUMENTS    DOCUMENT MANSER   DATE   COUNTRY   FIRE   SECURE   TRANSLATION																		
		The state of the s																	
			$\prod$		I	I	I					_				200	1909		
			$\prod$														<u> </u>		
			$\prod$											(	<u>۲۱۲.</u>	H 10	100		
				01	THE	ER	I D	00	CUN	MENTS	(Including Au	ntho	r. Title,	Dát	e, Pen	inent Pag	es. Etc.)		
			7	Bir	nde	ır Ç	Э. e	t al	J., °C	Deregula	ited simultane	ous	s expre	ssio	n of m	ultiple glud	cose transp	orter iso	ermote
P	12		$\dashv$	111	I I MA.	100	Ha.		. جدا ط	are nov	des ' vince.	<del></del>	Hese	1141,	11.46.	1	337].		
Ì	<i></i>										of cancers mi	SSO	d at sc	1001	ing ma	mmograp	hy, Radio	logy,	
M	M															<u> </u>			
	. 0															beled fatty	acid into	ardiac	
41	AL		$\prod$																
М	,																		lysis
	AK			Co	olvill	le (	C.A	<b>.</b> 6	et al.,	., "Analys	sis of the stru	ctur	raj requ	iren	ents c	f sugar bi	nding to the	e liver, b	
М							ılin	·re:	spon	nsive glu	icose transpo	rter	s expr	esse	d in o	ocytes," 6	liochem. J.	294:75	3-760
IF	AL										1 (18F)-FDG ir	n on	icology	r: a c	tinical	update", A	luc. Med. 8	Biol.	
	4			_							esigner Antis	ens	e Oligo	nuc	lectide	s: conjug	ation chem	tistry an	đ
М	PAR			fur	nctio	on	ality	y p	lace	ment," A	Antisense Res								
	EXAMIN	ER				っつ	,	1				ATI	E CÓV	ISID	EREC	9/			
				<u> </u>	_	Ľ	<u> </u>	1,	$\overline{}$					81	27	00	· 		
	through ci	itation if																	
- 1	applicant.	Chien K.R. et al. "In vivo esterification of a synthetic 125I-labeled fatty acid into cardiac glycerolipids", Am. J. Physiol. 245:H693-H697 (1983).  Coats E.A. et al., "Exploring the hexokinase glucose binding site through correlation analysis and molecular modeling of glucosamine inhibitors", J. Enz. Inhib. 6:271-282 (1993).  Cohville C.A. et al., "Analysis of the structural requirements of sugar binding to the liver, brain and insulin-responsive glucose transporters expressed in oocytes," Biochem. J. 294:753-760 (1993).  Conti P.S. et al., "PET and [18F]-FDG in oncology: a clinical update", Nuc. Med. & Biol. 23:717-735 (1996).  Crooke S. et al. (eds).: "Designer Antisense Oligonucleotides: conjugation chemistry and functionality placement," Antisense Research and Applications, Ch. 17, pp. 303-349, CRC Press. Boca Raton (1993).  DATE CONSIDERED  DATE CONSIDERED  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line brough citation if not in conformance and not considered. Include copy of this form with next communication to																	

/Melissa Perreira/

06/23/2006



	FORM PTO-1449  (REV. 8-83)  MAR 1 1993 a																
	INFORMATION DISCLOSURE CITATION  PROTECT AND TRADEMARK OFFICE  76958.P003  09/149,734  APPLEANT  Jesse Salb																
	(HEV. 8-8	53)	1	M	AD					51			76958.P00	3	09/	149,73	4
		ا	12				•			- 1	• 						7
	INFO	RMA	iy,	אל	4 (		S	CL	0	SUPRE CI	TATION						
		/I le		\$	70	40	)E)			3/ 100000000	al		9-8-98			t accia	
		103		346	ήrο	_	-	_	5 11	Hecessar	<u>'')                                   </u>		3.0.30		. not ye	Lassigi	ied
						_			_	U.S. PA	TENT DOC	U	MENTS				
ļ	*EXAMINER INITIAL		∞	cui	MEN	(T N	ene	BEF	_	DATE		ı	NAME	auss	SUBCLASS	FILING IF APPR	DATE OPRIATE
ME	AL		5	7	2	8	5	2	7	3/17/98	Singer et	al.		435	6	6/7	/95
MP	AL		5	7	2	9	6	2	0	3/17/98	Wang			382	128	5/10	)/95
MP	All		5	7	6	3	2	0	8	6/9/98	Bischofbe	rg	er et al.	435	40.5	2/28	3/96
				L	L	L	L	L									
				Γ	T	Γ	Γ										
		FOREIGN PATENT DOCUMENTS: 0.2 (20)															
	FOREIGN PATENT DOCUMENTS (12 (120))  COCUMENT MANSER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO																
			000	UME	BU	CLASS	SUBCLASS										
ı			Т	Γ	.44	<del>                                     </del>											
ł			╅	-	┝	╁	$\vdash$	$\vdash$	Н						<del> </del>		
		,	+	H	H	Ł	L	L	Н						<del> </del>		
	1	•	$\perp$	L	L	L	L	L	Ц			_			<u> </u>		
				0	Tŀ	ΗE	R	D	oc	UMENTS	(Including Au	uth	or, Title, Date, Perti	nent Pag	es, Etc.)		
													ng of c-myc oncoger				
М		ŀ								isense prot 63 (1994).	es in a mam	me	ary tumor-bearing m	ouse mo	del", J. Nuc.	Med.	
	AL			L	Ť	_				•							
м	,	l											lism of radiciodinate 1869 (1997).	d PHIPA	3-10 in the	rat	
"	AR	Ì		T					Ť								
	- "	$\dashv$		E	kh	oln	n S	).E	. e	al., "Neura	l tissue uptal	ke	and clearance of iot	exol folk	wing lumba	r myelo	graphy
MP	M			in	ra	bb	its	•	Ac	ta Radiolog	ica Diagnosi	<b>S</b> (	Stockh). 26:331-336	(1985).			
	10			L													
м													positive screening n 089-1096 (1998).	nammog	rams and cl	nical bre	east
M	AR			Ť	~~							<i>,</i>					
											registration a	an	d normalization of im	ages", F	luman Brain	Марріл	9
MP	AL	ŀ		2	:16	35-	18	9 (	199	95).			<del></del>				
J	7 100			Ļ													·
МВ	اما												cal parameters for the os III: Modeling hydi				
	AP									-90 (1988).	•			· -			
ŀ	EXAMIN			۲,	/14	· - 2	1 -	_	<i>a -</i>	Denna	dra/In	)Δ΄	TE CONSIDERED	,			
	u - u - u - u - u - u - u - u - u	· /	1	. /	171	. <del>.</del> .	L	7	ဆင့် မ	Perre	/		8/22/8	, .	6/23/2	006	
	*EVA1411**		77	<u>12'</u>	¥	<u>11</u>	<u> </u>	4	<u>'</u>	Territoria de la constantia del constantia de la constantia de la constantia della constantia della constant	742				ED 600- 0	!!	
		ation											on is in conformance lude copy of this for				•



				4			2	1	2					Sheet4	of _	10
	Form PT	•	49	(	7			_	•	POTENT NOT	ENT OF COMMERCE	ATTY, DOCKET NO.		SERIAL NO.		
	(REV. 8-1	53)		_				. •	••	9 👸 _		76958.P00	03	09/	149,73	4
			L	4	1A)	K U	<b>,</b> 1	۱ ۱ 	-	ध्र		APPLICANT				
	INFO	RM/	sy:	S.	ΝI	DI	S		0.	STIRE C	ITATION	Jesse Salb				
			se s				BAS			,		FLING-DATE		GROUP	•!-	
		10.	30 3		9/6	<u>~</u>		-	3 1	f necessar	<u>y)</u>	9-8-98		not ye	t assig	nea -
			_	_		_	_		_	U.S. PA	TENT DOC	JMENTS				
	PEKAMINER LINITIAL		٥	ocu	/MĐ	NT N	4.04	BEF	1	OATE		NAME	auss	SUBCLASS	FILING IF APPR	OATE OPRIATE
٠		A		1		L									İ	
				T	T	Γ	Γ		Г							
				I	I								7			
					Τ							:				
				T	Τ	Γ	Γ		П							<del></del>
	FOREIGN PATENT DOCUMENTS															
	FOREIGN PATENT DOCUMENTS															
	FOREIGN PATENT DOCUMENTS															
			Т	Т	Т	Т			П		<del>                                     </del>	<del></del>	AES	NO.		
			4	+	╀	Ļ	Ļ	L	Ц					ļ		
			4	↓	╀	L	L	L	Ц							
					L					. (				1		
				_	\			<u> </u>	20	LIMENTO	//					
	· · · · · · · · · · · · · · · · · · ·	-		_			_		_			hor, Title, Date, Pert			Canadia	
M	þ i									982).	ar odiner is un	permeable to metriza	DIUGS, A	ua Neuroi. S	ycanuini 	
	AL			T												
ME			_									1251-labeled metriz				
ME	1.1		_	5	ubi	<u> </u>	iqic	ital	in	jection in ra	bbit, rat, and o	at, Acta Radiol. Su	opl. S335	:300-311 (1	<del>973).</del>	
	1410		Ļ.	Ł				_		al Pinone	olotionobino b	etween lipophilic cha		d biological	a adia iida a	-4
											1):1-19 (Janua		nariai au	o olological	acuvity	<u> </u>
M	r Am I					-										
	7.13											damentals and appli	cations in	chemistry a	and biok	ogy'.
M			<u> </u>	╬	p. 1	<u>97</u> .	<u>-16</u>	8,	<u>Ar</u>	ner. Chem.	Soc., Washing	ton, DC (1995).				
	M			Ļ	<u> </u>		_	_	_							
	MP										100xy-5-iodo-( '. 24:527-534 (	)-glucose (6DIG).: a 1997).	potential	tracer of glu	cose	
	"HL			Ť				•								
	110	-	-	╁	łoh	C	.K.	et	al.	. "PET in or	cology: will it	replace the other mo	dalities?".	Seminars ir	Nuc. A	led.
ſΡ	ا مر									April 1997)						
	AK															
	EXAMIN	ER		_/	/M	 e]	li	s:	3 a	Perre	ira/ O/	TE CONSIDERED	)	06/00	/2004	
		IA.	[ M	√2	10	À	4.	,	l	Zodnia	1	alast.	d	06/23,	<i>-</i> 2006	,
	*EXAMINE		nitia	<u>ت.</u> انا ا	<u>: ت</u>	<u>IZ</u>		201	ازی:			tion is in conformance	<u> </u>	ED 600- D-	w line	
	through ci	lation	if n	ot i	in c	χοn	for	m	300	e and not o	considered. In	clude copy of this for	m with ne	ext commun	ication t	0
	l apolicant.															



		4	$\leq$	1	P	2					Sheet5	01	10	
Form PTO-			<u> </u>			_	U.S. DEPARTME	ENT OF COMMERCE	ATTY, DOCKET NO.		SERIAL NO.			
(REV. 8-83)	1		448				14		76958.P00	3	09/1	149,734	\$	
	\.	_					13 a)	<u>.</u>	APPLICANT					
INFOR	MAT	181	10	)IS	CL	0.	SUPPE C	ITATION	Jesse Salb		<u></u>		` _	
		1	£ 11	BAC	)F#	Y.R.	necessar		FILING DATE		GROUP			
	(USB	Sev	erai	-SA	Oct	<b>5</b> (	necessar	<u>y)</u>	9-8-98		not ye	t assigr	180	
							U.S. PA	TENT DOCU	MENTS	-				
*EXAMINER LAITINI	_	00CV	MENT	T MUI	MBEF		DATE		NAME	aass	SUBCLASS	FILING IF APPRO	DATE	
	_	_	Ц	4	$\downarrow$	L								
	_	_	Ц	$oxed{\downarrow}$	$\downarrow$	L							·	
		4	Ц	$oxed{\downarrow}$	1	L								
	+	4	H	$oxed{+}$	$\downarrow$	L		: :		*****				
	4	+	Ц	$oldsymbol{\downarrow}$	$\downarrow$	L				<i>y</i>				
		丄	Ш	Ц	$\perp$	L	<u> </u>	ļ	. ; : : :,	760				
							FOREIG	N PATENT (	DOCUMENTS					
FOREIGN PATENT DOCUMENTS  COMMENT NUMBER  DATE  COUNTRY  CLASS  SUBCLASS  TRANSLATION  YES NO														
		· · · ·			-	YES	МО							
							l	L			_L			
		П	П	Π	Τ	Γ					1			
		╁┼	H	H	十	t	<del>                                     </del>	<del> </del>		_	<del> </del>	<b></b>		
		Щ	Ш	Щ	_L	L	l	L						
		c	)TF	1EF	a Di	00	CUMENTS	(Includina Aut	thor, Title, Date, Pert	inent Pad	385. Elc.)			
									s of lodine-123-BMIP			ium afte	<u></u>	
MP		<u>lr</u>	egic	onal	l isc				cations for clinical SF					
106		ľ	199	<del>1</del> 7).										
	$\top$	- 1		•			•	flip-flop in ph	ospholipid bilayers is	extreme	ly fast, Biod	hemistr	<del>y</del>	
MP	$\vdash$	- 13	4:1	192	28-1	19	137 (1995).	<del>.</del>						
AL												,,		
MP			(am	ip F	. et	al M	., "Moveme hilavers". <i>Bi</i>	ent of fatty acid inchemistry 32:	ls, fatty acid analogu :11074-11086 (1993)	es, and l ).	oile acids ac	TD\$8		
	H	-	110	SPI II	Oup.		Unayora , D.	od romotry oz						
APL	_	.	Cola		- 00	al	*Spectral	considerations	for absorption-edge	fluomec	ony Medic	al Physi	<u></u>	
MP							n/Feb 1977				ору ,осло			
AL	Γ										•			
<del></del>	+	٠,	(elc	z F	. et	al	., "Absorptio	n-edge fluoros	scopy using a three-s	pectrum	technique",	Medical	,	
MP	L	1	Phy	sics	s 3(	<u>3):</u>	159-168 (M	ay/June 1976)	·					
AL		1												
P		1	Z:-O	er T	r.H. odifi	et	al., Synthe:	sis and hybridi ides". <i>Nucleic</i>	zation properties of c Acids Res. 21(19):4	oligonuci 499-450:	eotides conta 5 (1993).	ining		
AL		Ť												
EXAMINE	▃┴		<del></del> ,					/ D	ATE CONSIDERED	)			•	
)	٢٠	~{}	[]  []	Me ()	<u>÷</u> لر:	Z	sa Peri	retra/	8/22	100	06/	23/20	006	
'EXAMINE	a: Ini	tial if	cit	atio	U C.	יייי			tion is in conformanc	e with M	PEP 609: Dr	aw line		
through cita	tion if	not	in c	nox	om	ar	nce and not	considered. In	clude copy of this fo	m with r	ext commun	ication (	10	

		1	$\overline{a}$	P	E					Sheet6	of	10		
Form PTO-	- 1					COPPLETINE	OF COMMERCE PADEMARK OFFICE	ATTY, DOCKET NO.		SERIAL NO.				
REV. 8-83)	-1		44 D (	η .		8 &		76958.P00	)3	09/1	49,73	4		
	1.	•				. મુનુ	<del>.</del>	APPLICANT						
INFORM	MATI	JN.	DIS	CLO	os	URE C	ITATION	Jesse Saib						
		13	S TR	ADER	AARY	-		FILING DATE		QROUP				
(	Use se	ever	al sh	eels	il n	ecessar	y) ·	9-8-98		not ye	t assigi	ned		
						U.S. PA	TENT DOCL	JMENTS						
EXAMINER INITIAL	∞	CUME	ENT NUI	MBER	T	DATE		NAME	auss	SUBCLASS	FILING IF APPR	DATE OPRIAT		
	十	П	П	П	$\dagger$									
	+	$\dag \uparrow$	$\dagger\dagger$	$\dagger\dagger$	+				-	<del> </del>				
	+	$\dag \dag$	$\dagger\dagger$	$\dagger\dagger$	十			<del></del>	-	-	-			
	+	$\dag \dag$	$\dagger\dagger$	$\dagger\dagger$	+			<del> </del>		<del> </del>				
	+	$\dag \dag$	+	+	+					<del> </del>				
<del></del>		₩	₩	╁	╀		<del> </del>			<del> </del>	ļ ——			
		Ш	Ш	Ш	$\perp$		<u></u>	<del></del>	<u> </u>	<u> </u>	<u> </u>			
						FOREIG	N PATENT I	YYCHMENTS						
——————————————————————————————————————					TRANS	ATION								
	000	WEN	IT NUME	COUNTRY	CLASS	SUBCLASS	YES	NC						
	Т	П	П	П										
		₩	₩	-		├	<del> </del>							
		Ш	Ш	Ш						1.	1	L.		
		Π	П	П	T									
L		1.1.					<u> </u>		<del>!</del>	<del></del>	·	<b></b>		
DOCUMENT NUMBER   DATE   COUNTRY   CLASS   SUBCLASS														
	$\top$	Ko	man	ю М.	et a	d., Toxic	ity of X-ray co	ntrast media in cell c	ultures",	Invest. Rad	ioł. 15:6	8-71		
MP	$\vdash$	(19	<del>)</del> 80).											
AX	1													
1	1							gonucleotide transpo	ort into liv	ing cells", F	roc. Na	d.		
MP	-	AC	ad. S	ia. U	JSA	86:3474-	3478 (1989).							
		L												
VD.		Ma	ichull	a H.	J. et	al. Com	parative evalu	ation of fatty acids la ardium: concise com	beled wit	h C-11, Cl-3	4m, Br∙7 Mod	7, a		
MP	<b> </b> -	_	:298-				s of the myoc	ardium. concise com	Hunicau	JII , J. 140G.	MOCL			
					•									
MR						al., "Isolat Feb 1979		ges using spatial-free	quency e	ncoding, M	ied. Phy	\$.		
		1	17.50	-50 (	<del>000</del>	1 00 1010	,,.	<u> </u>			-			
<del></del>	+							ited glucosamines ar	nd their e	effect on hex	okinase	•		
MP		ᄬ	3iol. (	Chen	n. 21	14:765-77	3 (1955).							
							otide analogu	es: an overview, Cit	a Found	ation Sympo	sium 20	9,		
MP			5-11				stract							
AL	-							ion method for estim	ating oct	anol-water p	artition			
EXAMINER							Sci. 84(1):83-9	2 (1995). ATE CONSIDEREI						
IVIII4EF	File	n/.	/Me //		S \$7	Pen	ceira/	4/22	Ind	06/23/	2006			
· · · · · · · · · · · · · · · · · ·	100	, <del>v</del>		, 0		-w	1001	0100	100	050 000 0				
EXAMINER	i: Initia	ulifici notin	Itatio	orm:	nsid: ance	ered, whe	ther or not cits considered to	ition is in conformant actude copy of this fo	M ruw e: I diw mı	rer 609; Di 1ext commu	raw une nication	to		
applicant.					ى ماد مى <u>ن</u>	, 4.4 101						-		



			↫		<u> </u>	€-	_							She	961	of _	
Form PTC			0		Ų	J.S. DE	September 1	ENT OF COM	MERCE	ATTY.	DOCKET			SE	RIAL HO.		
(REV. 8-8	3)	1		- 0			1			<u></u>	769	58.P00	)3	L	09/1	149,73	4
		1_				1553	6.7	-		APPLI							
INFOF	ITAM	Ob)	Dis	SCL	.08	SUF	E/C	OITATIO	N	Jes	se Sa	ID					
		/	17	TRA	เทย					FILING	BTAG E			o o	ROUP		
	(Use s	ever	al S	hee	7	TIBC	essai	(Y)	<u>.</u>	<u></u>	9-	8-98		_	not ye	t assig	ned
— т	-,-			<u>.                                    </u>	_	Ų.	S. P	ATENT D	OCL	JMEN	TS		<u>,</u>				
'EXAMINER INITIAL	~	CUME	ENT M	JABES	₽ 	0.	ATE		_	NAME			auss	1	SUBCLUSS	FILING	O DAT
	+	╫	+	+	H									+			
		$\dagger\dagger$	$\dagger \dagger$	$\dagger$	H			<del> </del>				٠, ٠٠٠ و٠		$\dagger$			
		#	11	+	$\dagger \dagger$						÷.	• • • • • • • • • • • • • • • • • • • •	***	+	15		
		$\prod$		T							:	:::			,		
		$\prod$			$\prod$						٠:	; j. (	ED 17 4	1	·-		
						FC	REIO	GN PATE	NT (	ocu	MENT	rs					
	~	ZAMEN	7 M 12	4060	Т	0.4	TE	T -		COUNTRY	,		auss	Т	SUBCLASS	TRANS	LATIO
		T T			-			ļ						4		YES	- NK
		H	Ш		П									1			
		$\dagger \dagger$	П	$\top$	П			·1						+			T
	- 1	11	- 1 - 1	i I	1 1												
		11	$\top$	+	Ħ			+				····	<del> </del>	┿		<del>                                     </del>	⊢
		П			$\prod$									1			
					$\prod_{\infty}$	1 13 45	AITS	C (la abudia	- 4.4		We De		Y	1			
								6 (Includin								004)	
мр								Glucose I								994).	
		Mu	iecki Ison	C.A	4., °1	Facili	tative Targe		ransp	porters	r, Eur.	J. Bioc	hem. 21	9:71	13-725 (1		e?".
MP AY		Mu	iecki Ison	C.A	4., °1	Facili	tative Targe	glucose t	ransp	porters	r, Eur.	J. Bioc	hem. 21	9:71	13-725 (1		e?".
AL		Mu Ne J.	ison Nucl	C.A L. Me	A., *1 L et ed 37	Facili al., * 7:103	tative Targe	glucose t	ıcose	porters	port pa	J. Bioc	hem. 21 or turnor	9:71 ima	13-725 (1 ging: is it	feasibl	
MP AY ME		Ne J. I	ison Nucl	C.A L. Me	4., *1 L et ed 37	Facili al., *7:103	Targe 11-103	glucose to eting of glu 37 (1996).	ransp	trans	port pr	J. Bioc	hem. 21 or turnor	9:71 ima	13-725 (1 ging: is it	feasibl	
AL		Ne J. I	ilson Nucl	C.A L. Me	4., *1 c et ed 37 et al	al., "7:103	Targe 11-103 yocan	glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to glucose to	graph	trans	1-123 1987).	J. Bioconteins for	or turnor	9:71	13-725 (1 ging: is it as a test	feasible	
AL		Ne J. i Ra he:	ilson Nucl nilton art d	C.A L. Me	4., "I L et ed 37 et al see",	Facili al., "7:103 i., "M , Eur	Targe 31-103 yocan o. J. A	eting of glucose to string of	graph 13:63	trans y with 3-68 (1	Port port port port port port port port p	J. Bioconteins for the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of the present of th	or tumor ocanoic a Veinhein	9:71 ima ncid	13-725 (1 ging: is it as a test p. 1-43 (1	feasible for core 992).	
AY. ME ME		Ne J. I Ra he:	ison Nucl iiiton art d	C.A L. Me R. 6 lisea r, R.I	A., "I Let et al et al ise",	al., "M 7:103	Targe 31-103 yocan o. J. A	ating of glucose (string of glucose).  37 (1996).  dial scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintic scintis scintis scintis scintic scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scintis scinti	graph 13:6:	trans y with 3-68 (1 Lipoph	Port pro-	J. Bioconteins for heptade	or tumor canoic a Veinhein	9:71 ima ncid n, pr	13-725 (1 ging: is it as a test p. 1-43 (1 ces between	feasible for core 992).	onan
AL		Ne J. I Ra he:	ison Nucl iiiton art d	C.A L. Me R. 6 lisea r, R.I	A., "I Let et al et al ise",	al., "M 7:103	Targe 31-103 yocan o. J. A	eting of glucose to string of	graph 13:6:	trans y with 3-68 (1 Lipoph	Port pro-	J. Bioconteins for heptade	or tumor canoic a Veinhein	9:71 ima ncid n, pr	13-725 (1 ging: is it as a test p. 1-43 (1 ces between	feasible for core 992).	onan
AY ME	P	Ne J. I	uscki Ison Nucl Lilton and d skker eden oros	C.A. Me	et all see",  J. et	Facili al., "7:103 I., "M , Eun t al., deo i	Targe 31-103 yocan yocan o. J. M "Calca Three mage	ating of glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to glucase to gl	graph 13:63 Drug	trans trans y with 3-68 (1 Lipoph e imag	I-123 1987). milicity,	J. Bioconteins for the prade volume use volume use to dine use to	hem. 21 or tumor ocanoic a Neinhein sing diffe	9:71 ima acid n, pr	13-725 (1 ging: is it as a test p. 1-43 (1 ces between the ces between test per ces between test per ces between test per ces between test per ces between test per ces between test per ces between test per ces between test per ces between test per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces pe	feasible for core 992).	g 19
AY ME	P	Ne J. I	uscki Ison Nucl Lilton and d skker eden oros	C.A. Me	et all see",  J. et	Facili al., "7:103 I., "M , Eun t al., deo i	Targe 31-103 yocan yocan o. J. M "Calca Three mage	ating of glucose to string of	graph 13:63 Drug	trans trans y with 3-68 (1 Lipoph e imag	I-123 1987). milicity,	J. Bioconteins for the prade volume use volume use to dine use to	hem. 21 or tumor ocanoic a Neinhein sing diffe	9:71 ima acid n, pr	13-725 (1 ging: is it as a test p. 1-43 (1 ces between the ces between test per ces between test per ces between test per ces between test per ces between test per ces between test per ces between test per ces between test per ces between test per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces per ces pe	feasible for core 992).	g 19
AL MF MI	P	Ne J. I	uecki ilson Nucl uilton art d ekker oros	R. G. R. G. G. R. G. G. R. G. G. R. G. C. C. R. G. C.	et al ese", F. et	Facilial, "M, Eun tal., Eun deo i	Targe 11-102 yocannon J. A. Calcumage mage	ating of glucose (string of glucose (string of glucose).  Idial scintification of lateral scinti	graph 13:63 Orug (-edgrical c	oorters transporters transporte	port pro- li-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1	J. Bioconteins for the ptade of VCH, North odine uses, Medical odine used. Physical ptages of the ptade of the ptade of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptages of the ptag	or tumor canoic a Neinhein sing diffe Phys. 8 sing diffe s. 8(4):44	9:71 ima acid n, pr	ging: is it as a test p. 1-43 (1 ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between the ces between t	feasible for core 992). een (Jul/Au	g 19
AL MF MI	P	Rahen Rieffun	uscklison Nucliiton and dekker edernoros	R. G. R. G. R. G. R. G. R. G. R. G. C.	et all set.  J. et c vic.  J. et c vic.  d. et all set.	Facilitation of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of th	Targe 11-103 Three mage Three mage desi:	ating of glucose (1996).  Indial scinting of glucose (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).	graph 13:63 Orug Georgical c	transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters trans	I-123 987).  Iiiig of ing of i	J. Biocopteins for the ptade volume us, Med volume us, Med volume us, and Exer Institute volume volu	or tumor veanoic a veinhein sing differs. 8(4):44 nd Rasultute. 42 pt. 12 pt. 12 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 14 pt. 1	9:71 ima- ima- n. pp aren. 3(4):	13-725 (1 ging: is it as a test p. 1-43 (1 ces betw 471-479 ces betw 187 (JuVA	feasible for con- 992). een (Jul/Au een aug 198	g 19
AL MF MI	P P	Rahen Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffu	ueckl ulson Nucl uiton ant d nicker eden oros	I R. ( isea of S. Copi	A., "I et al se",	Facility al., "M., Eun it., "M., Eun it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al., it al.,	Targe \$1-100 Targe \$1-100 Three mage Three mage	ating of glucose (1996).  Indial scinting of glucose (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial sc	graph 113:63 Orug Gedgical c	transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters trans	P. Eur. 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-12	J. Biocopteins for the ptade volume us, Med volume us, Med volume us, and Exer Institute volume volu	hem. 21 of tumor ocanoic a Neinhein sing diffe . Phys. 8 sing diffe s. 8(4):44 nd Rasul tute, 42 Biol. Ch	9:71 ima acid n, pr eren 8(4): aren 80-4 tts P	13-725 (1 ging: is it as a test as a test p. 1-43 (1 eces betwie 471-479 eces betwie 87 (Jul/A eces betwie 1998).	feasible for con- 992). een (Jul/Au een aug 198	g 19.
AX ME MI MPAR	P P	Rahen Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffung Rieffu	ueckl ulson Nucl uiton ant d nicker eden oros	I R. ( isea of S. Copi	et al se',	Facility  al., "M.  7:103  I., "M.  Eun  t al.,  deo i  al. (e ics R  Sub	Targe \$1-100 Targe \$1-100 Three mage Three mage	ating of glucose (1996).  Indial scinting of glucose (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial scinting (1996).  Indial sc	graph 113:63 Orug Gedgical c	transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters transporters trans	P. Eur. 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-123 1-12	J. Bioconteins for the ptade of VCH, Notice of the ptade	hem. 21 of tumor ocanoic a Neinhein sing diffe . Phys. 8 sing diffe s. 8(4):44 nd Rasul tute, 42 Biol. Ch	9:71 ima acid n, pr eren 8(4): aren 80-4 tts P	13-725 (1 ging: is it as a test p. 1-43 (1 ces betw 471-479 ces betw 187 (JuVA	feasible for con- 992). een (Jul/Au een aug 198	g 19.



					/	$\sqrt{c}$	1	<u>P</u>	<u>E)</u>		•		Sheet8	of _	10
Form			19	/				U.S.	DEPARTIC	OF COMMERCE	ATTY, DOCKET NO.		SERIAL NO.		
(REV	. 8-8	3)		- [		MA	• 1		123	• 1	76958.P00	)3	09/	149,73	4
				\.	~			-	- L	<b>4</b>	APPLICANT				
INI	FOF	RMA	TIC	$D N_{j}$	Ų.	SC	CLC	SU	JRE	TATION	Jesse Salb				
					1	્	PAI	DEM			FILING DATE		GROUP		
L		(Us	0 S	9V81	ral	she	ets	if ne	cessa	(y)	9-8-98		not ye	t assig	ned
									U.S. P	ATENT DOC	JMENTS				
EXAMIN AFTINI	NER L		00	CUME	ENT:	NUM	BEA		DATE		NAME	CLASS	SUBCLASS	FILING IF APPR	DATE OPRIATE
				П	T		П	Г							
	-	$\dashv$		H	╁	+	╫	╁	<del></del>	<del>                                     </del>		<del> </del>	<del> </del>		
				Ц	↓	Ш	Ц	L					]		
	,]			П	ł	1		ı							
	-	-		H	+	T	H	╁╴		<del> </del>		<del>                                     </del>	<del> </del>	-	<del></del>
				11	1		П	•		j					
		$\neg$		Ħ	Ť	1	П	Т			• • •		,		
				Ш	1	L	Щ	<u>!</u>	<u> </u>		<u> </u>	<u> </u>	L	·	
	FOREIGN PATENT DOCUMENTS														
	FOREIGN PATENT DOCUMENTS														
			000	UMEN	πM	UMBE	P		DATE	(	COUNTRY	CLASS	SUBCLASS	TRANSL	MOITA
	$\dashv$		T	Т	Т	T	П	╁		<del>                                     </del>			<del> </del>	1.63	~
	_		4	Ц	4	Ц	Щ	↓_	_					Ļ.,	
			1		ł							1	İ	1	
			十	H	t	Ħ	T	T					<b>——</b>	_	
	_1		ــــــــــــــــــــــــــــــــــــــ	Щ		لل	LL	<u> </u>				<u> </u>	<del> </del>		
	•			от	Н	ER	000	CUR	IENTS	(Including Au	thor, Title, Date, Pert	inent Pan	es Etc l		
			_								ated contrast media",	-		1-13. C	hurchill
M	IP								1988).				ос.с, рр.		
A	4	- 1		1	•										
1		$\neg$	_								f human beta-cell glu			logy to	he
MP		-		cry	sta	l st	ructu	ite c	f yeast	hexckinase B	, Diabetes 43:784-79	91 (1994)	•		
										0.00					
	МР										onucleotides with po	sitron em	ission tomo	graphy"	,
	-	ŀ		Ma	lur	e m	ewa.	<i>1119</i> 4	<del>(4).40</del> /	<u>'-471 (1998).</u>					
W.		- 1								ise 1 study of t <i>ucl. Med.</i> 28:68	eta-methyl-p-(123I)- 11-690 (1991)	iodophen	yl-pentadec	anoic a	cid
МР		ľ						1 - 7				-			
-	$\dashv$	-		Trie	nat	ti A	l et	l al	The e	Hect of intracel	lular pH on long-chai	n fatty aci	d untaka in	3T2.11	
1	MP	L									es the passive diffus				fatty
				aci	ds	acre	oss t	ne p	lasma	membrane", <i>Bi</i>	ochem. J. 313:487-4	94 (1996)			
<del> </del>	+	-+		var	n Ö	ijck	J.A.	et a	J., 'The	current detect	ability of breast canc	er in a ma	ımmograph	ic scree	ning
ME	1	L		pro	gra	am.	A re	vein	of the	previous mam	mograms of interval a				
^T				Ca	nc	er 7:	2(6):	193	3-1938	(Sept 15, 1993	).				
EXAM	VINE			_						0.4	TE CONSIDERED		06/23/	2006	
	1/	1.		./1	Mg/	li	<b>S</b> B)	Ì	Perre	eira/	11771	(11)	00,20,	_ 000	
	<u> </u>	T//	<u> </u>	101	4	2_				102	8/04	<u>w</u>			
											tion is in conformance clude copy of this for				
applic											<del></del>		m, wanningii		-



					6	11	P	13					Sheet 9	of _	10
Form PT	-	49	7				U.S.	DEPARTY	ENT OF COMMERCI TRADEMARK OFFICE	:	ATTY, DOCKET NO.		SERAL NO.		
(REV. 8-8	33)		1	,	MAI			- 2	1	٦	76958.P00	3	09/1	149,73	4
			1-	•				SS 🤶	L-	ı	APPLICANT				
INFO	RMA	ATIC	Уc	ক্	(IS	CLC	SL	JASIC	ITATION		Jesse Salb				
			•	V	<u>ک</u> ،	AAD1	24.5	11.5			FILING DATE		<b>GROUP</b>		
	(Us	io se	3 <b>V</b> 81	ral	shi	१	Tric	ecessa.	ny)		9-8-98		not ye	t assigi	ned
								U.S. P	ATENT DOC	U	MENTS				
'EXAMINER INITIAL		∞	CUM	ENT	NULL	BEA		DATE		_	NAME	auss	suscess	FILING IF APPR	OPRIATE
			П	1	T										
			$\prod$	1	†	П	T		$\top$				1		
	П		П	T	T	П	T		1		<del>-,,,</del>				
· · ·	П		$\dagger \dagger$	†	†	$\parallel$	T			-	<del></del>				
			П	1	T	П	T				•		,		
= = =			П	1	T	$\prod$	T								
	<u> </u>					· * * : : .	<u> </u>								
		000	(ME)	NT N	AMB	er e	T	DATE	T	α	DUNTRY	auss	SUBCLASS	$\overline{}$	<del>,</del>
		$\top$	П	Т	Т	П	十		+	_	· · · - · · · · · · · · · · · · · · · ·		+	163	<del></del>
		_	Ц	4	1	4	丄		<u> </u>				<del> </del>	ļi	<u> </u>
0				1	L										
					T										
			0	тн	FR	no	CUI	MENTS	(Includina Au	utt	hor, Title, Date, Perti	inent Pac	nes Etc.)		
<b>1</b> (D)			Va	an E	Een	ige N	М.J. 4	et al., "C	Clinical value o	of s	studies with radiolog	tinated h	eptadecanoi	c acid in	1
MP		<del> </del>	pa	tie	nts '	with	coro	nary an	tery disease*,	<u> </u>	ur. Heart J. 11:258-2	268 (199	0).		
ME			Ļ					<del></del>	.,,.						
MP								., "A revi (1991).		iga	ative mammography	in a sym	ptomatic pop	vilation	, Clin.
											•				
МΡ									rrelation conce ancer Res. 13:4		t: ordered pattern of -77 (1972).	gene ex	pression in r	neoplasi	a*.
		$\overline{}$													
											ind anomalous gene	express	ion in expen	imental	
MP			he	pa	tom	89 <sup>-</sup> ,	Çan	ICEF HES	s. 32(10):2007	·21	016 (1972).				
H,	ſΡ		W	ills	on I	VI. et	al.,	Yeast	hexokinase inl . 12:101-121 (	hit	bitors designed from	the 3-D	enzyme stru	icture	
\ "	r		+	Đų.	HQui	<u>g . v</u>	. 611	Z. 1111110.	. 12.101-121 (	<u> </u>	997).				
1/1	MР		W	001	ds f	1.P.	et al	., "Auto	mated image	16	egistration: I. Genera sist. Tornogr. 22(1):1	method	ts and intras	ubject,	
AK.	11.	_	1	l ear	noc	anty	Vau	dauon ,	J. Compat. A.	136	ist. romogn zaviji	33-132 (	1530].		
EXAMIN				7	Μе	ندا	986	a, Per	rreira C	DA	TE CONSIDERED	)			
	H	m	Eu.	d	10	` <u>⊀</u>	/		us		8/22/08	<u>ر</u>	06/23/2	2006	
EXAMIN	IER: I	Initial	J if c	ital	tion	con	sider	red, who	ether or not cit	tati	ion is in conformance	e with Mi	PEP 609; Dr	aw line	
through capplicant		i if n	ot in	1 00	onto	mai	nce :	and not	considered. I	Inc	clude copy of this for	m with n	ext commun	ication (	10

7

						_						Sheet 10	of	10
Form PTO-14 REV. 8-83)	49	$\nearrow$	O	•	-	ATEN ATEN		NT OF COUNT WOEMARK OF	FICE	ATTY, DOCKET NO. 76958.P	003	SERIAL NO.	49.734	
WE004		¥	(AR	0	1 19	<b>19</b>	<b>:</b>	T47104		APPUCANT  · Jesse Salb				
INFORM	41K	N.	UI	SCI	LO	SUN	# CI	IATION	4			GROUP		
///	co c	X	Sita	D			ssarj	۸		FILING DATE 9-8-98			assign	had
- 10.	30 3	JVON	a CS		10 1	21000	3301)	<u>"</u>		3-0-30	<del></del>	1101 98	assigi	
<del></del>	_				_	U.	S. PA	TENT DO	CL	MENTS				
EXAMINER INITIAL	~	CUME	NT N	UMBE	<b>*</b>	DATE				HAME	auss	SUBCLASS	FILING IF APPRO	DATE
		Щ		Ц	Ц					·····			·	_
	_	$\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!$	$\downarrow$	$\coprod$	$\coprod$						_			
	-	$oxed{\sqcup}$	+	$oxed{\downarrow}$	$\coprod$					· ·		**		
	$\vdash$	╁	+	╁	H					- :-				
·	-	H	+	╁	H									_
	<u> </u>	<u></u>		Ш	Ш								<u> </u>	
						FO	REIG	N PATE	יוו נ	OCUMENTS				
	000	MENU	IT NU	MBER		DA	TE	1	COUNTRY CLAS			SUBCLASS	TRANSL	NO
	Ţ	П	T	П	П					•	<del> </del>	<del> </del>	163	~
	$\dashv$	H	$\dagger$	H	H		_	<u> </u>	•		-	†		
	_	$\dagger \dagger$	t	H	Ħ							<del> </del>		
, , , , , , , , , , , , , , , , , , ,		ОТ	HE	R C	200	UME	NTS	(Including	Аи	hor, Title, Date, P	ertinent Pa	nes. Etc.)		
		Wo	ods	s R.I	P. el	al.,	Auton	nated imag	) (e	gistration: II. Inter	subject vali	dation of line	bns and	
MP	-	noi	nun	ear r	moa	els", .	J. Con	nput. Assis	n. 1	omogr. 22(1):153-	105 (1990).			
MP.							MRI-P /Aug1		abo	with automated a	ugorithm",	J. Comput. A	ssist. To	mogr.
AL												-		
	L	_										_		
	<u> </u>	1	_					<u> </u>	. —			·		
	-	-										-		
	$\vdash$	+									<u> </u>	<del></del>	<del></del>	
	-	+								<del></del>				
	$\vdash$	十							_				<del></del>	
		+			_			<del> </del>			<del></del>			
EXAMINER	.l		/1	Me]	lie	ssa	Per	reira	1	ATE CONSIDER	ED 06	/23/20	06	
*EXAMINER:	Initia	d if c	itati	on c	onsi	derec		ther or not	cita	tion is in conforma	nce with M	PEP 609; D	aw line	

	(1) = 4.0-0	∼,					
	INFO	RM/	ATIC	N	) C	)IS	30
17910		(U	se se	ve	ra	l s	he
FB 0 7 2000 50							
	"EXAMPLER INITIAL		00	CUN	KEN	T NO	UM
Manager Park	MP/L		5	7	9	8	9
	• 4						

			_	_			_	_											Sheet		of_	
	FORTH PTO-1449 U.S. DEPARTMENT OF COMMER PATENT AND TRACEMARK OFF									MERCE OFFICE	ATTY, DOCKET NO. SERIAL NO. 09/149,734						14					
INFO	RM/	<b>NTIC</b>	м	1 (	ונ	S	c	1 C	ารเ	JRF	_ CIT	ATIO	N	1	icant SSB S	alb						
			•	• •		_	_	_	,,,,	, <u></u>	. 011	A110	14	FLIN	G DATE				GROUT	,		
	(Us	e se	ve	re	1/ 5	sh	86	ts	if n	eces	sary)					9-8-9	8		n	ot ye	t assig	ned
									<del></del>	U.S.	PAT	ENT D	OCL	MEN	πs			<b></b>			<b></b>	
EXAMPLER INITIAL	NER DOCUMENT NUMBER DATE								NAME CLASS					\$UB	auss	FIL IN	G DATE ROPRIATE					
MP(//		5	5 1 9 8 9 7 7 3					7	7 3	3/30/1993 Salb							364	413.01	11/27/199			
			$\vdash$	H	H	ŀ	+	+	+			╂					÷	ļ	-			
			┝	-	+	1	$\dagger$	$\dagger$	+	<del></del>	, <del></del>	<del> </del>					**		+-			
			t		t		†	$\dagger$	$\dagger$			<del> </del>							1			
					I		1													_		
	_									FOR	EIGN	I PATE	NT (	DOCI	JMEN	vTS						
		000	ŲMĮ	91	ľ M.	,Dad	86	<b>-</b>	Τ	DATE	<del>- 1</del> -			COUNTR				CLASS SUBCLASS TRANSL				SLATION
		T	Γ	Γ	Τ	Ţ	1	T	T		$\top$											
									I													
						ļ					$\perp$											<u> </u>
			0	T	HE	ĒF	۱ ۽	00	CU	MEN	ITS (I	ncludin	g Au	thor,	Title, l	Date.	Pert	nent Pa	ges, E	tc.)		
			Ļ																			
	_	_	ł		_	_																
			╀		_			_														
•			T			-		_			•				<del></del>							
			I																			
		_	1	_	<del>-</del>				2													
	-	_	+			_		_	_					.,				_				
		-	+		_		_	-								-						
		$\vdash$	$\dagger$																			
			1		_	_																
	ER	-	/M	_	7 -				D	orr	eir	a /	D	ATE	CON	SIDE	REC	100	06/	22/1	2006	
EXAMIN		•		٠.	<u> </u>	LZ	3 5	ج ا	) <sup>-</sup>	֓֓֞֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֓֓֓֓֓֡֟֓֓֓֓֡֓֓֓֓֡֓	LUI	<u>u,</u>				11	27	1.00	00/	43/4	2006	



					-								۲ -				
Form I	PTO-	1449	(Mod	lified)	Atty Docke	t No	·:		Seria	I No.		70-	2 7 700	े ी			
					076958.P00	)3			09/14	9,734		WE 2 TOO S					
		•			Statement		_	Applic	ant:		·	V	TA TRAD	3.5			
(Use s	evera	il she	ets if	necessary	') ·		-	Jesse S									
						<del>-</del>	<del></del>	Filing	Date:	Septer	nber 8, 199	<del>)</del> 8					
REFER	RENC	E D	ESIGI	NATION			U.S. P/	ATENT I	DOCU	MENTS							
Examir	er			Docume	ent No.						Class	Sub-	Filin	g date			
Initials				<u> </u>								Class	if ap	propriate			
MP /	46		AA	5,093,0	42	Co	unsell e	t al.			260	408	4/20	/90			
			_AB	<u> </u>		┞			·			<u> </u>					
			AC			<u> </u>						ļ					
		_	_AD			<u> </u>						—					
		-	AE			┼					<del></del>	┼					
		$\dashv$	AF	<del> </del>		┼			<del></del>			<del> </del>					
		+	AG		<del></del>	╀						<del> </del>					
		$\dashv$	AH			╁						+	_	<del></del>			
		$\dashv$	Al			┼					<del></del>	┼──					
		$\dashv$	AJ AK	1		$\vdash$											
	-				<del></del>	<del></del>	- p to					1		<del></del>			
				•	FO	REIC	TAG NE	ENT DO	CUME	NTS							
No.			Docu	ment No.	Date	Date Co		untry			Class	Su	ib- ass	Trans-			
	A																
	Al	$\overline{}$															
	A	N															
	A	0											<u></u>				
	A	Р	****								<u>.l.</u>		<del></del>	<u></u>			
				OTHER	ART (Includ	ding	Autho	r, Title,	Date, F	Pertiner	nt Pages, e	itc.)					
MP	_	AF			al., "Metaboli and. Vol. 72 p				plicatio	n of me	trizamide t	o rat bra	in corte	k," Acta			
		7	$\overline{}$		et al., "Cardi				Subce	ellular ic	calization	of uro-a	ngiograp	hic			
MP A	(	AS			125I-labeled												
мрд			١	lordby A.	et al., "Intrace	ellula	r penet	ration ar	nd accu	ımulatio	n of radiog	raphic c					
Exami		A			ey" (and disc erreira/			consider		. <del></del>	, 031-000		/2006				
CXAIIII	1/1	r r	and	.,,	rique Z		Date	/O11310011	<	3/27	100	06/23	/2006	_			
EXAM					considered, v	whet	her or n	ot citatio	n is in	conform	nance with	MPEP 6	309; Dra	w line			
					nance and no												
apolica																	



Form	PTO	-144	9 (Mod	ified)	Atty Docket	No.:	··· <i>_</i>	Serial N	o.:		6	w ·	a l
					076958.P00	3		09/149,7	34	(	MR 2	( )	
List of	Pate	nts a	ind Pu	blications	Statement		Applic				An.	JOE S	
(Use	ever	al sh	eets if	necessary	<i>(</i> )		Jesse :	Salb.			ANEM &	Russ	
				-			Filing	Date: Se	ptemb	er 8, 199	8	- 1 - 1 × 1	
REFE	REN	CE D	ESIGN	IATION	·	U.S. P	ATENT I	DOCUME	NTS				
Exam	ner			Docum	ent No.				Cla	ass	Sub-	Filin	g date
Initials	<u> </u>					~					Class	3	propriate
<u> </u>			AA	ļ									
			AB	<u> </u>								<u> </u>	
			AC	<del>                                     </del>		_						<del>                                     </del>	
			AD	<del> </del>								↓	<del></del>
			AE	1						<del></del> -		<del> </del>	· · · · · · · · · · · · · · · · · · ·
<del></del>			AF	+		<del></del>				<del></del>		╁	· · · ·
			AG AH	<del>-}</del>						-		┼─	
			Al	<u> </u>						•		<del> </del>	<del></del> ·
			AJ								<u> </u>	1	
			AK									1	
No.	Ţ		Docur	nent No.	FOF	REIGN PA	TENT DO	CUMENT	s	Class	Sub-	,	Trans-
				•							Clas	3	lation
	A									·	_		
<u> </u>	A			i									<del> </del>
	A						<del>.</del>				<del></del> -		
-	A	P						<del></del>					
<b>70.0</b>				OTHER	ART (Includ	ling Autho	or, Title, I	Date, Pert	inent F	eges, et	c.)		dan
MP			N	ordby A. e	t al., "Effects	of radiogra	aphic con	trast medi	a on m	onolayer	cell cultu	res,"	Invest.
	4C	Al	RR	adiol. Vol	. 21 pp. 234-2	239 (March	1986).					•	
МР	1				P. et al., "Poly		• •	•	•			omogr	aphy
	1	A:	2   III	aging age	ents for the liv	er, J. Me	J. Unem.	voi. 38 N	o. 4 pp.	000-046	(1335)		
		A	<u>r                                    </u>										
Exam	ner	A	/M		Perreira/		Considere	8/2-	rlw	. 00	6/19/20	06	
EXAM	INEF				considered, w		not citatio	n is in con	forman	ce with M	APEP 60	9; Drav	w line
_		tion	if not i	n conform	ance and not	considere	d. Includ	e copy of	this for	m with ne	ext comm	unicat	ion to
applic	ant.												,

25/26)

			olications S necessary)	/	(U)			t: Jesse S		1000	<del> </del>
				A TO	1 200 G	3	Filing Da	te: Septen	iber 8,	1998	
REFE	RENCE	DESI	GNATION	A PADEMA	MARKE	PATENT	DOCUME	NTS			
Examir Initials	ner		Documen	t No.				Class	Sub- Class		g date propriate
MP	#L	AA	4,887,60	4	Shefe	er et al.		128	654	05-	16-1988
		AB									
		AC AD			<del>                                     </del>	<del></del>			+-		
		AE									
		AF									
		AG AH	<del> </del>	·	<del> </del>			-	_		
		AI		<del>-</del>	<b>-</b>						
		AJ					· · · · · · · · · · · · · · · · · · ·				
		AK AL		<del></del>	<del> </del>			<del></del>	+		
		AM			•					_	
		AN									
		AP	ļ		<u> </u>						
				FOR	EIGN	PATENT	DOCUMEN.	TS			
No.		Docum	nent No.	Date	<del>- 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100</del>	Country		Class	S	ub-Class	Trans- lation
N	AQ		70 340	06-08-		Europe					
AL	AR	WO 98	3/57669	12-23-	1998	WIPO					
	AT			-		l T			_		<u> </u>
	AU										
		ОТН	ER ART	(Includir	ig Aut	hor, Title,	Date, Pe	rtinent Pa	ges, et	tc.)	
M	AV	PCT In		Search R	eport fo	or PCT Int'l A	Appin No. PC	T/US99/202	298 mail	ed April 2	25, 2000
7.4		(, pag	<del> </del>							10	
	AW	<del> </del>	<u>.</u>					<del></del>		1	<del>- =</del>
	AX			•							= :-:
	AY		···			· · · · · · · · · · · · · · · · · · ·					<u>ت</u> الراجع
	AZ						·			- 53	
	ner 1	/Mali	rssa) Per	reira/	Date	Considered	2.1	22/00	06/2	3/2至06	

26/26)